Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.
Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors.
The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Thomas H. Jensen |
Contact Details
Address: 24 School St., 2nd Floor Boston, Massachusetts 02108 United States | |
| Phone | 401-426-4664 |
| Website | allarity.com |
Stock Details
| Ticker Symbol | ALLR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860657 |
| CUSIP Number | 016744104 |
| ISIN Number | US0167443029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer, Senior Vice President of Investor Relations and Director |
| Joan Y. Brown | Interim Chief Financial Officer |
| Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. | Co-Founder |
| Dr. Steen Meier Knudsen Ph.D. | Founder and Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2024 | 8-K | Current Report |
| May 24, 2024 | 8-K/A | [Amend] Current report |
| May 21, 2024 | 8-K | Current Report |
| May 17, 2024 | 424B5 | Filing |
| May 15, 2024 | 8-K | Current Report |
| May 15, 2024 | 424B5 | Filing |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 424B5 | Filing |
| May 9, 2024 | 8-K | Current Report |
| May 8, 2024 | RW | Filing |